



Open Government Impact Statement

81st Oregon Legislative Assembly
2021 Regular Session

Measure: SB 763 - A

Only impacts on Original or Engrossed
Versions are Considered Official

Prepared by: Cameron D. Miles
Date: 4/27/2021

SUMMARY

Provides that person may not engage in business as pharmaceutical representative without obtaining license from Director of Department of Consumer and Business Services. Specifies application requirements and procedures, required qualifications of licensee and basis on which director may issue, renew or reinstate license. Prescribes certain duties of and prohibits certain actions by licensee. Enables director to punish violations of Act by suspending, revoking or refusing to renew or reinstate license.

Takes effect on 91st day following adjournment sine die.

OPEN GOVERNMENT IMPACT

Legislative Counsel has not adopted standards for drafting measures that establish exemptions from disclosure of public records.

This measure exempts from public disclosure personally identifiable information of a pharmaceutical representative, licensed by the Department of Consumer and Business Services, contained in the annual report the licensee must file with department.

If those public records that could be subject to public disclosure were instead subject to mandatory disclosure under public records law, the public could receive information regarding business practices of individual pharmaceutical representatives.